Physician profile
Marc A Sciarra
NPI 1760894083
$2,296.57
in general payments reported to CMS, 2019-2025
27 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $458 · 2021: $893 · 2022: $283 · 2023: $82.05 · 2024: $239 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $567.83 | 2019-2025 | Farxiga |
| Pfizer INC. | $179.31 | 2020-2025 | |
| Lilly USA, LLC | $147.98 | 2020-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.49 | 2021-2025 | Jardiance |
| Smith+Nephew, INC. | $78.29 | 2020-2023 | Grafix Pl |
| Amgen INC. | $70.89 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $57.09 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $56.26 | 2020-2022 | |
| Amarin Pharma, INC. | $55.31 | 2020-2021 | |
| Esperion Therapeutics, INC. | $49.52 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $46.94 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $45.59 | 2025 | Rexulti |
| Mylan Specialty L.P. | $40.57 | 2021 | |
| Solventum Corporation | $27.35 | 2024 | Activ.A.C. |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.05 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $24.16 | 2024-2025 | Voquezna |
| Dexcom, INC. | $22.52 | 2021 | |
| Kci USA, INC. | $21.20 | 2020 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Glaxosmithkline, LLC. | $18.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.50 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.92 | 2021 | |
| Cashflow Solutions, LLC | $12.96 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Merck Sharp & Dohme LLC | $12.19 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.89 | 2021 | |
| Roche Diagnostics Corporation | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Sciarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.